<DOC>
	<DOCNO>NCT03030586</DOCNO>
	<brief_summary>The objective ADDIA clinical Proof-of-Performance study validate performance ADDIA ' blood biomarkers diagnosis Alzheimer 's disease . ADDIA clinical study multi-centre , non-interventional , prospective , proof-of-performance study one visit . About 800 well-characterized subject recruit 3 group 2:1:1 ratio , namely patient Alzheimer 's disease ( AD ) , patient non-AD neurodegenerative disease ( NAD ) 200 control subject ( healthy compare age ) . - 400 patient Alzheimer 's disease ( AD ) , - 200 patient non-Alzheimer 's neurodegenerative disease ( NAD ) , - 200 control ( healthy compare age ) .</brief_summary>
	<brief_title>ADDIA Proof-of-Performance Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<mesh_term>Frontotemporal Lobar Degeneration</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<criteria>For group : Male female subject , age 50 85 year . Signed date write informed consent obtain subject subject 's legally acceptable representative ( applicable ) accordance local regulation . AD , NAD patient control subject agematched mean age similar three group . Able comply study procedure . For AD group : Diagnosis AD Specific clinical phenotype AD : Presence early significant episodic memory impairment . Gradual progressive change memory function report patient informant 6 month . Objective evidence amnesic syndrome hippocampal type , base significantly impaired performance episodic memory test ( Dubois et al , 2014 ) . MMSE score 25 21 subject mild AD &lt; 21 patient moderate severe AD . FCSRT MoCA test compatible AD diagnosis . Neuroimaging compatible diagnosis AD : structural 3D MRI ( volume hippocampus cortical area ) , neuroimaging data ( e.g . PET Amyloid scan FDG PET ) practice clinical centre shall compatible AD diagnosis . Cerebrospinal fluid biomarker data show positive level least 2 3 biomarkers , Aβ142 , phosphorylatedTau totalTau . For NAD group : Frontotemporal dementia : Diagnosis behavioral variant FTD ( bvFTD ) accord Rascovsky et al. , 2011 . The following finding must present : Criteria possible bvFTD . Functional decline ( Clinical Dementia Rating Scale Functional Activities Questionnaire score ) . Imaging result consistent bvFTD [ one follow must present ] : Frontal and/or anterior temporal atrophy MRI . Frontal and/or anterior temporal hypoperfusion hypometabolism PET SPECT ( retrospective data available ) . Note : case familial form bvFTD , subject must member family know mutation one FRD related gene , MAPT , PGRN . Note : If take acetylcholinesterase inhibitor and/or memantine treatment , subject must take medication ( ) ≥3 month . MMSE &gt; 21.MoCA FCSRT test perform . Neuroimaging : volumetric structural MRI find compatible bvFTD CSF biomarker data must show negative level three least two three CSF biomarkers Aβ142 , phosphorylatedTau totalTau . Neuroimaging : volumetric structural MRI find compatible bvFTD . Parkinson 's disease dementia ( PDD ) : Subjects Parkinson 's Disease Dementia ( PDD ) dementia develop Parkinson 's disease ( PD ) . PD diagnose 3 typical PD symptomatic finding : tremor , rigidity slow movement ( bradykinesia ) . Note : Subjects dementia LRRK2 gene mutation mutation one follow gene : PARK2 SNCA , VPS35 , PINK1 , DJ1 , ATP13A2 , FBX07 , SLC6A3 , TAF1 also include . LDOPA responsive . Cognitive score : MMSE score 2125 mild PDD ; MMSE score &lt; 21 moderate severe PDD . MoCA FCSRT test perform . Structural MRI : Evidence relevant structural abnormality ( i.e . basal ganglia Parkinsonism potentially mediotemporal cortical finding may relate dementia ) . Retrospective Fluorodopa PET SPECT data available shall document presence dopaminergic dysfunction . CSF biomarkers show negative level three least two three CSF biomarkers : βamyloid 142 , PhosphorylatedTau TotalTau . Lewy body Dementia ( DLB ) : DLB diagnose dementia occur concurrently Parkinsonism . Patients diagnose probable DLB accord two follow criterion : Fluctuating cognition pronounce variation attention alertness , Recurrent visual hallucination typically well form detail , Spontaneous feature Parkinsonism , OR Patients diagnose probable DLB accord one criterion one follow criterion : REM sleep behaviour disorder , Severe neuroleptic sensitivity , Low dopamine transporter uptake basal ganglion ( SPECT PET image ) . Note : familial form cause mutation gene SNCA , SNCB DLB include . MMSE score : 1025 , MoCA FCSRT test perform . MRI : Relative preservation medial temporal lobe structure . CSF biomarkers : negative level three least two three CSF biomarkers : βamyloid 142 , PhosphorylatedTau , TotalTau . Progressive Supranuclear Palsy ( PSP ) : Diagnosis probable possible PSP define National Institute Neurological Disorders Stroke Society Progressive Supranuclear Palsy ( NINDSSPSP ) diagnostic criterion Gradually progressive disorder , Onset age 40 later , Vertical ( upward downward gaze ) supranuclear palsy prominent postural instability tendency fall first year disease onset , No evidence disease could explain foregoing feature , indicate mandatory exclusion criterion . Be able ambulate stand unassisted 5 minute . Be able cooperate gait balance test . MMSE score &gt; =21 , FCSRT MoCA test perform . Brain MRI consistent PSP : neuroradiologic evidence relevant structural abnormality midbrain frontal lobe ( i.e . basal ganglion , lobar atrophy ) . CSF biomarkers : negative level three least two three biomarkers : βamyloid 142 , PhosphorylatedTau , TotalTau Corticobasal degeneration ( CBD ) : Diagnosis possible CBD describe study protocol ( Armstrong et al . 2013 ) . Inclusion clinical criterion possible CBD , feature CorticoBasal Syndrome ( CBS ) . Progressive Supranuclear Palsy Syndrome ( PSPS ) include . Familial form related MAPT include . Features CBS : ) limb rigidity akinesia , b ) limb dystonia , c ) limb myoclonus plus 1 : ) orobuccal limb apraxia , e ) cortical sensory deficit , f ) alien limb phenomenon ( simple levitation ) . Features PSPS : Three : ) axial symmetric limb rigidity akinesia , b ) postural instability fall , c ) urinary incontinence , ) behavioural change , e ) supranuclear vertical gaze palsy decrease velocity vertical saccade . Note : subject probable sporadic CBD ( familial form ) exclude . Cognitive test : MMSE &gt; =21 , MoCA FCSRT test perform . Structural MRI finding : parietal cortical atrophy ( asymmetric ) , basal ganglion atrophy corpus callosum . CSF biomarkers : negative level three least two three CSF biomarkers : βamyloid 142 , PhosphorylatedTau , TotalTau . Control group : Normal cognitive performance . MMSE score ≥26 . Normal FCSRT score . Normal MoCA score . Normal finding Neuroimaging : Structural MRI : Normal 3D volumetric score . Normal find βamyloid PET scan perform . Normal find neuroimaging method perform . Retrospective CSF biomarkers available negative level three CSF biomarkers : βamyloid 142 , PhosphorylatedTau , Total Tau . Exclusion Criteria group : The follow exclusion criterion apply three group : Psychiatric history : schizophrenia , psychosis . Infection disease , chronic inflammatory disease ( affect structure and/or function blood cell ( cell ADDIA biomarkers measure ) /patients active infection/ immunosuppressive disorders/ treatment immunosuppressive immunomodulatory medication Vascular dementia . Subject take medication interfere cognitive function ADDIA biomarkers ( list study protocol eCRF ) . Major sensory deficit could interfere cognitive assessment ( visual auditory ) . Epilepsy . Neutropenia ( Neutrophils &lt; 1,500/mm3 accord ethnic group ) Thrombocytopenia ( platelet : &lt; 100,000/mm3 , rule EDTAinduced pseudothrombocytopenia ) . Subjects less elementary education exclude If medication insurance mandatory country , subject medication insurance exclude . Current past diagnosis malignancy affect blood cell ( currently treat stop since less 3 month ) . Patients know contraindication MRI image MRIincompatible stent MRIincompatible endoprosthesis . Subject sign inform consent . Alcoholism . Exclusion criterion AD group : Mixed dementia . Other dementia type besides AD . Other neurodegenerative disease besides AD . Absence CSF biomarker data ( and/or βamyloid PET scan data ) exclusive criterion subject sporadic form AD . Exclusion criterion NAD group : AD diagnosis . Mixed dementia . Vascular dementia . Absence CSF biomarker data sporadic DLB PDD absence CSF biomarker data and/or βamyloid PET scan data sporadic CBD , PSP exclusive criterion . Note : exclusive criterion subject familial form NAD due mutation gene among MAPT , PGRN , SNCA , SNCB , PARK2 SNCA , VPS35 , PINK1 , DJ1 , ATP13A2 , FBX07 , SLC6A3 TAF1 , TREM2 . Exclusion criterion Control Group : Alzheimer . Dementia . Cognitive impairment .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Blood cell biomarkers , peripheral circulating biomarkers</keyword>
</DOC>